- AddressBakerIDI Heart and Diabetes Institute
Dr Xiaowei Wang
Research Officer, Atherothrombosis and Vascular
Research Focus: Molecular imaging, Targeted drug therapy, Conjugation of contrast agents
Dr Xiaowei Wang graduated with a Diploma in Cardiac Technology at Singapore Polytechnic and worked as a cardiac technologist at the National Heart Centre for 3 years. She moved to Australia, where she was given a 2 years advance standing, and completed her Bachelor degree in a year. She was awarded the Dean’s Honours list at the University of Melbourne for her Honours thesis, which focuses on clinical ultrasound of the brain in the Neurology department. Xiaowei then received 2 full scholarships and an additional top up scholarship to do her PhD, which she completed in 2012. Dr Wang’s PhD research spanned across several scientific fields, including physics, chemistry biology and biotechnology, and required both basic research and translational development of a future diagnostic tool to be used in patients.
Her major research focus is molecular ultrasound imaging, including the development of targeted contrast agents and targeted drug therapy. Her work has been published in high impact factor journals such as Circulation, Nature Protocol, Blood and Circulation Research. Dr Wang has been awarded the International Research Award from the Australian Society for Medical Research, 9 international travel grants for conference presentations and 4 Young Investigators Awards, as well as being nominated as Ralph Reader Prize Finalist for CSANZ 2011. She is on the program committee for both the Australia Society of Molecular Imaging (ASMI) scientific meeting and the World Molecular Imaging Congress held in Korea in September 2014, as well as the pioneering working group of ASMI.
Xiaowei has been awarded the National Association of Research Fellow Award 2014, the International Society of Heart Research Postdoctoral Publication Prize 2014 and is supported by the National Heart Foundation Postdoctoral Fellowship with the Paul Korner Innovation Award.
Hagemeyer CE, Alt KJ, Ohnaton APR, Such GK, Ta HT, Leong MKM, Prabhu S, Wang X, Caruso F, Peter K. Particle generation, functionalization and sortase A-mediated modification with targeting antibodies for diagnostic and therapeutic use. Nature Protocols 2014; accepted.
von Elverfeldt D, Maier A, Duerschmied D, Braig M, Witsch T, Wang X, Mauler M, Neudorfer I, Menza M, Idzko M, Zirlik A, Heidt T, Bronsert P, Bode C, Peter K, von Zur Muhlen C. Dual-contrast molecular imaging allows noninvasive characterization of myocardial ischemia/reperfusion injury after coronary vessel occlusion in mice by magnetic resonance imaging. Circulation 2014;130(8):676-87.
Wang X, Palasubramaniam J, Gkanatsas Y, Hohmann JD, Westein E, Kanojia R, Alt K, Huang D, Jia F, Ahrens I, Medcalf RL, Peter K, Hagemeyer CE. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res 2014;114(7):1083-93.
Hohmann JD, Wang X, Krajewski S, Selan C, Haller CA, Straub A, Chaikof EL, Nandurkar HH, Hagemeyer CE, Peter K. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding? Blood 2013;121(16):3067-75.
Wang X, Hagemeyer CE, Hohmann JD, Leitner E, Armstrong PC, Jia F, Olschewski M, Needles A, Peter K, Ahrens I. Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice. Circulation 2012;125(25):3117-26.